Indian drug firm Glenmark has lost a patent case against US firm Abbott Laboratories over hypertension drug Tarka. Subsequently it will pay $16 million in damages to the US firm. As a result, shares of Glenmark fell sharply on the BSE and the NSE. Glenmark was selling generic Tarka, at-risk, in the US markets since June 2010.
